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ABSTRACT 
Hepatitis C virus (HCV) is a public health epidemic effecting 3.5 million people in the United 
States alone.  The uninsured, underserved residents of a rural county in North Carolina have 
limited access to screening and early detection for HCV.  Through collective efforts, a free 
medical clinic partnered with a grant funded, nonprofit organization to provide free hepatitis C 
testing by use of a mobile medical unit. The aim of this study was to determine if use of an HCV 
screening tool would increase the number of patients screened for testing as compared 
retrospectively to the number of patients screened without use of the HCV screening tool.  
Methods included retrospective data from chart audit, patient survey of at-risk HCV behaviors 
including the birth cohort 1945-1965, and a pretest/ posttest measure of provider knowledge on 
HCV before and after an educational intervention.  The sample population consisted of a 
retrospective group R(n=52) and a prospective group P(n=49).  The screening outcome of each 
group resulted the following: R(n=52) confirmed screening 13 out of the 52 (25%) participants 
without use of a screening tool while the P(n=49) group captured 43 out of 49 (82.7%) 
participants with the implementation of a screening tool.  Participant gender for the study 
included males 44.6% and females 55.4 %.  The most common risk factor for HCV was birth 
cohort (1945-1965) 30.2% followed by Intravenous drug use 11.6%.  Lastly, results of the pretest 
/ posttest exhibited a 20.8% increase in HCV provider knowledge.  
 
 
 
Keywords: baby boomer, birth cohort 1945–1965, free medical clinic, HCV screening, 
hepatitis C, IV drug abuse, medically uninsured  
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SECTION ONE: INTRODUCTION 
Lack of access to medical care for uninsured and underserved populations in rural 
counties continues to burden the entire health care system.  In the United States, millions have 
been infected by hepatitis C virus (HCV), but less than half have been diagnosed (Turner, Craig, 
Makanji, Flores, & Hernandez, 2017).  Despite the recommendations of the Centers for Disease 
Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF), 
accessibility and resources for HCV screening are not at all equitable across populations.  A 
public health epidemic, an estimated 3.2 million Americans are living with HCV infection, and 
approximately 19,000 people die from HCV-associated liver cancer or chronic liver disease each 
year (Jorgensen, Carnes, & Downs, 2016).  Early detection, diagnosis, and treatment of HCV are 
far more cost effective than treating the grave end-stage sequalae.  HCV often goes undiagnosed 
due to lack of presenting symptoms until the late stages of disease progression.  Consequently, 
failing to timely diagnose HCV will lead to unbearable symptomatic liver disease, cirrhosis, 
hepatocellular carcinoma, and/or death, all of which could be avoided with appropriate 
screening.  Increased awareness and strict adherence to screening policies in baby boomers and 
high-risk populations are paramount in order to diagnose HCV infection early, offer therapy, and 
prevent HCV-related mortality and morbidity (Mahgoub et al., 2018). 
Accessibility and equity in rural areas are multifactorial.  Aside from the lack of available 
providers and services, unemployment and poverty create barriers to funding and insurance.  The 
Appalachian foothills of North Carolina are filled with small towns that historically developed 
around a single industry such as furniture or textiles.  The rural county of Petersboro suffered 
significantly in the 1990s when industries began moving overseas, leaving workers jobless.  
Further demise of the local economy resulted from the loss of two major automotive sport races 
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in 1996.  This loss of revenue caused people to leave and businesses to close, thus crippling the 
economy in the immediate area.  Over 20 years later, the community still struggles.  In 2017, the 
rates of unemployment and poverty in Petersboro County, North Carolina, were higher than the 
rates of unemployment and poverty in the United States as a whole (U.S. Census Bureau, 2018).  
This is not a new trend in rural geographical locations.  Statistical data of unemployment and 
poverty rates of the Petersboro area correlate with the accessibility and equity of healthcare in 
the community.  Also noteworthy is the uninsured rate (Table 1; U.S. Census Bureau, 2018).  
Urban America believes they extend service outreach to fill this equity gap, but the statistical 
disparity of rural America tells another story.  
Table 1 
Comparison of Demographics of Petersboro County and the United States 
 Peters County (%) United States (%) 
Unemployment 4.3 4.1 
Poverty 21.1 12.3 
Uninsured 27.4 10.2 
Disabled 18.7 12.6 
Note. The data are adapted from U.S. Census Bureau, 2018. 
In many areas, Appalachian mountain health practices are still culturally acceptable, and 
modern-day preventive healthcare historically has been viewed as nonessential.  Often, families 
use treatment methods passed down generation to generation to avoid the cost of medical care.  
Lack of knowledge of preventive healthcare services, coupled with the burden of screening cost, 
contribute to this view of traditional healthcare as unnecessary.  This lack of accessibility, equity, 
and community knowledge led to the creation of the Samaritan Free Medical Clinic (SFMC) in 
Petersboro County.  Created in 2010 by a local doctor who wished to help the less fortunate and 
hurting in the community, the clinic offers completely free medical care services to anyone, 
regardless of income.  SFMC operates as a 501(c)(3) with monetary donations from local 
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community businesses and churches, and 100% of donations are used to treat patients.  Local 
providers, nurses, lab technicians, medical assistants, and office personnel volunteer to serve 
those in need of medical care.  Screening is vital to promote prevention and, more importantly, 
the quality of life in the foothills.  Improving adherence to screening recommendations and the 
manner in which they are conveyed to the public is critical to implementing the national viral 
hepatitis action plan and thereby increase diagnoses and avert new infections (Martin, Norcott, 
Khalid, & O’Connell, 2017). 
Background 
HCV has been called a silent epidemic.  Unfortunately, most HCV-infected persons are 
asymptomatic and unaware of their status (Ditah et al., 2015).  Due to the expansion of illicit 
drug use and contaminated transfusions that occurred in the 1970s and 1980s, HCV infection is 
particularly prevalent in the baby boomer population (those born between 1945 and 1965); this 
birth cohort accounts for up to 75% of all HCV infections (Galbraith et al., 2015).  As HCV is a 
curable public health epidemic, screening can lead to treatment of individuals infected with the 
virus and prevent the progression of liver disease to cirrhosis, hepatocellular carcinoma, and the 
associated morbidity and mortality (Joshi, 2014). 
Hepatitis-acute versus chronic. Variations of HCV include acute and chronic disease 
processes.  Acute HCV occurs within the first six months after exposure to the HCV and is a 
short-term illness (CDC, 2016).  Unfortunately, 75%–85% of acute infections convert to chronic 
HCV disease, which, when left untreated, causes severe health problems including liver-related 
death (Dan, Moses-Eisenstein, & Valdiserri, 2015).  Due to the lengthy lag time between 
infection and the appearance of symptoms, it is expected that rates of cirrhosis and hepatocellular 
cancers will increase over the next 10–13 years (Moyer, 2013).   
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Risk factors. The USPSTF (2016) has stated with moderate certainty that screening for 
HCV infection in adults at increased risk for infection and one-time screening in adults in the 
1945–1965 birth cohort has moderate-net benefit.  The USPSTF identifies HCV as a grade of B 
to medical providers, which states best practice is to provide HCV screening (USPSTF, 2016).  
The CDC also recommends screening and list guidelines for HCV screening.  According to CDC 
(2017), at risk-adults are those who meet one or more of the following criteria: 
• past or current injection drug use                             
• received a blood transfusion before 1992 
• long-term hemodialysis  
• born to an HCV-infected mother 
• incarceration 
• intranasal drug use 
• got an unregulated tattoo  
• other exposures (needle sticks, surgery born universal precautions) 
• sex with an injection drug user 
• born between 1945 and 1965 
Patients born between 1945 and 1965 are more likely to be diagnosed with HCV infection, either 
because they received a blood transfusion before the introduction of screening in 1992 or 
because they have a history of other risk factors for exposure from decades earlier (Moyer, 
2013).  Lack of symptoms is a barrier to screening.  According to findings from a study reported 
in the Journal of Viral Hepatitis, the most common reason for not testing among all participants 
was “I do not think I have any risk factors” (Grannan, 2017, p.634).  To help implement HCV 
guidelines and recommendations, the CDC developed Know More Hepatitis, a national, theory-
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driven multimedia education campaign aimed to ultimately reduce the morbidity and mortality 
associated with HCV by increasing testing among baby boomers so those who are infected can 
receive life-saving care (CDC, 2016). 
Testing. Administering HCV screening to determine if diagnostic testing is warranted 
currently requires a two-step process.  The CDC’s updated algorithm for screening recommends 
subjects who test HCV positive from point-of-care testing then complete a nucleic acid testing 
(NAT) to determine whether chronic HCV infection is present (Khuroo, Khuroo, & Khuroo, 
2015).  NAT is also termed HCV-RNA testing.  The World Health Organization (WHO) is 
working toward simplifying the testing process to one step in the near future with the goal of 
making screening both cost effective and easily accessible (Hellard, Chou, & Easterbrook, 2017).  
Treatment. Appropriate screening and early detection will allow HCV-positive patients 
to seek linkage to care for access to appropriate treatment.  The primary goal of treating HCV 
patients is to achieve sustained virologic response (SVR), which has been shown to reduce the 
risk of downstream advanced liver complications, including mortality (Younossi, Yushan, Smith, 
Stepanova, & Beckerman, 2015).  Tremendous advancement has been made with the availability 
of sensitive diagnostic tests and highly effective direct-acting antivirals (DAAs) capable of 
achieving SVR in more than 95% of patients (Saab, Le, Saggi, Sundaram, & Tong, 2018).  The 
new DAA treatments fall into three main classes of target-specific drugs that disrupt the viral 
replication cycle of HCV: NS5A, NS5B, and NS3 protease inhibitors.  Treatment of HCV usually 
includes a combination of at least two of the three drug classes with or without Ribavirin for 12–
24 weeks of therapy.  Achieving SVR, or no detectable virus (HCV-RNA) in the blood 12 weeks 
after completion of therapy, renders the individual cured of HCV (Surjadi, 2018).  Development 
of novel DAA oral drugs, proven to be safe and highly effective, further supports the increased 
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benefit of screening patients at risk and includes the essential one-time screening for baby 
boomers (Cornett, Bodiwala, Razuk, Shukla, & Narayana, 2018).  
Problem Statement 
Less fortunate patients in rural Petersboro County do not receive the CDC- and USPSTF-
recommended HCV screening.  Lack of accessibility to care and/or knowledge of the disease 
process along with key barriers of unemployment, low socioeconomic levels, and absence of 
insurance lead to disparity in health care between regions.  Unbeknownst to many, federal and 
state funding is often available in higher-poverty areas; only about half of people eligible for 
income-related programs actually enroll (Wilensky, 2017).  Patients with undiagnosed HCV will 
suffer end-stage liver morbidity and accrue more publicly funded healthcare expense, both of 
which could be prevented with screening, early detection, linkage to care, and treatment.  
Purpose of the Project  
The purpose of this project is to determine if using a screening tool would create an 
increase evaluation effort at the SFMC.  The objective was to utilize the HCV screening tool to 
increase the number of patients screened during the April 13, 2019, clinic period.  
Clinical Question  
At Samaritan Free Medical Clinic, how does the implementation of an HCV screening 
tool affect the HCV screening rate over a single clinic period when compared the previous clinic 
month when no screening tool for HCV was utilized? 
SECTION TWO: LITERATURE REVIEW  
Search Strategy  
A comprehensive electronic database search was conducted using the following 
databases: CINAHL, Healthsource, Medline, and PubMed.  A search for articles written in 
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English within the past five years using the search terms baby boomer, birth cohort, hepatitis C 
screening, injection drug use, underserved population in healthcare, and medically uninsured 
resulted in a list of 135,733 journal articles.  To taper the search, the search term and was added 
in advanced settings, followed by the removal of injection drug use and population in 
healthcare, reducing the count to 594 articles.  Articles were narrowed down further according to 
the quality of the study and relevance to the topic.  Bibliographies were scanned as another 
source of review.  A search concentrating on only peer-reviewed scholarly publications with full 
text ultimately returned 74 articles, of which 29 contained relevant information and were utilized 
in the literature review.  
Critical Appraisal 
The literature search uncovered various types of evidence to support the necessity of 
alternative approaches for HCV screening.  Importantly, it would be unethical to provide 
screening without ability to test and treat.  Efficacy for point-of-care HCV-antibody testing, 
HCV-RNA confirmation testing, and treatment with DAAs has made HCV curable for even the 
uninsured through alternative approaches.  All articles were reviewed for quality and appraised 
using the Iowa Model Attachment 5.2: Summary and Synthesis Tool (Iowa Model Collaborative, 
2017).  Each article was also examined for level of evidence according to Melnyk’s system of 
hierarchy (University of Michigan Library, 2018).  The literature findings included systematic 
reviews, clinical practice guidelines, controlled trials, mixed-method studies, and observational/ 
descriptive studies pertaining to HCV testing and the at-risk, uninsured population.  
Systematic review. Elimination of HCV is not an unreachable goal.  Tremendous 
advancements with DAA agents can achieve an SVR over 90% in HCV infections, and 
tolerability has increased the pool of patients eligible for therapy (Saab et al., 2018).  A 
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systematic review by Saab et al. (2018) reported on the elimination efforts of HCV in an effort to 
ascertain the possibility of eliminating HCV using established public health qualifying criteria 
(Saab et al., 2018).   
Saab et al. (2018) described criteria of technical feasibility to include practical and 
sensitive diagnostic testing and a surveillance program.  While the diagnostic tests themselves 
are sensitive and speciﬁc, there is still room for improvement in the way these tests are used to 
increase case identiﬁcation and link patients to specialized care (Saab et al., 2018).  A study from 
the University of California Los Angeles Health reported an increase in HCV screening of 145% 
after successful implementation of an HCV screening reminder in the electronic health record (as 
cited in Saab et al., 2018).  Methods to increase HCV screening still need further exploration. 
HCV surveillance in the United States has been ongoing since 1982, but the program is 
chronically underfunded, as only seven jurisdictions are funded by the CDC (Saab et al., 2018).  
HCV infection is more prevalent among marginalized groups, such as the homeless, prisoners, 
and intravenous drug users, who have little or no access to health care (Saab et al., 2018).  
Utilization of health departments, emergency departments (EDs), and free clinics create a lack of 
reporting; thus, the prevalence rate of HCV is inaccurate.  This study highlighted the need for 
additional community outreach programs to administer screening tests among high-risk 
populations along with the employment of a dedicated database for HCV surveillance (Saab et 
al., 2018).  
Effective interventions to prevent the transmission of disease include syringe and needle 
exchange programs (SNPs), opioid substitution therapy, and mental health services.  For 
example, SNPs have been demonstrated to reduce HCV transmission rates among injectable drug 
users by as much as 29% (Saab et al., 2018).  Significant barriers to public interventions include 
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state laws prohibiting pharmacy sale of syringes and needles and lack of funding for 
interventions programs and screenings.  Furthermore, without SNPs, reinfection with continual 
intravenous drug users is of high concern. 
Saab et al. (2018) disclosed field-proven strategies reported from organized efforts in 
Georgia, Egypt, and Australia that have made progress toward the elimination of HCV.  Initial 
success has been achieved by establishing national committees with strong government support 
and university health care systems.  Georgia launched a national campaign in 2015 to target 
high-risk groups (e.g., intravenous drug users, prisoners, patients with HIV) that led to the 
identification of 50,962 HCV antibody–positive individuals, with 59% of those confirmed to 
have chronic HCV infection (Saab et al., 2018).  By partnering with pharmaceutical industry, the 
campaign offered DAAs free of charge, which increased the average number of patients 
receiving treatment monthly by 300% in 2016 (Saab et al., 2018).  Egypt established a National 
Committee for Council of Viral Hepatitis and opened more than 54 centers to manage 800,000 
chronic HCV patients.  The committee also uses a national database to monitor HCV elimination 
progress (Saab et al., 2018).  Australia has had success through two strategies: funding and 
access.  First, the government invested 1.6 billion USD to expand HCV treatment access to all 
affected adults and negotiated lower DAA prices.  Second, the medical community was able to 
increase the proportion of DAA treatment prescribed by a general practitioner from 8% to 31%, 
thus increasing treatment accessibility tenfold from the previous year (Saab et al., 2018).   
In the United States, Saab et al. (2018) mentioned the efforts of the Veterans Affairs 
health care system, which has screened 2.9 million patients (53% of the total Veterans Affairs 
population) for HCV; of those with HCV viremia, 23% have initiated treatment, which is 
reported as higher than the national average (Saab et al., 2018).  Despite the screening efforts, a 
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significant barrier in the Veterans Affairs system is high treatment cost, which forces providers to 
prioritize patients that receive treatment.  All the aforementioned efforts certainly present 
learning opportunities moving forward.  
The final leg of this Saab et al.’s (2018) review discussed the social and political 
challenges surrounding the stigma of HCV populations.  The readiness of DAAs is hopeful, but 
they only help if patients have funding and access to screening and medical care.  The current 
lack of political support and pervasive social stigma continue to pose significant barriers for 
interventions to reach the most vulnerable populations (Saab et al., 2018).  Legislators and social 
advocates must focus efforts to change policy on SNPs and funding.  In 2016, the National 
Academy of Science, Engineering, and Medicine published a national strategy report that 
identiﬁed HCV as a signiﬁcant threat to public health that must be addressed.  The report 
explored the feasibility and barriers that must be overcome to eliminate HCV in the United States 
(Saab et al, 2018).  The WHO published a similar advocacy brief highlighting an elimination 
strategy, and the CDC has made several attempts to promote HCV awareness.  May has been 
designated by the CDC as Hepatitis C Awareness Month to encouraging screening of high-risk 
populations.  Saab et al. (2108) stated correctional facilities are an ideal setting to screen and 
educate a high-HCV prevalence population, but this opportunity has been largely neglected; any 
intervention program in this population will be highly impactful (Saab et al., 2018). 
The results of this systematic review highlight the need for additional community 
outreach programs to administer screening among high-risk populations and the need for 
technical feasibility, economic considerations, and social and political attention to accomplish 
this goal (Saab et al., 2018).  Several countries have taken steps to eliminate HCV; however, with 
its technological advances and existing infrastructure, the United States has the potential to 
 A HEPATITIS C SCREENING TOOL FOR AN UNINSURED POPULATION 
  20 
become the first nation to eliminate HCV if it can secure public support and political 
commitment (Saab et al., 2018).   
Meta-analysis. Khuroo et al. (2015) conducted a comprehensive systematic review and 
meta-analysis of studies that assessed the diagnostic accuracy and applicability of point-of-care 
tests for HCV.  Khuroo et al. (2015) found enough information to enable an evaluation of the 
performances of several individual tests and established a protocol that included several aspects 
of the meta-analysis, following the guidelines of the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis. 
In the meta-analysis, all the tests performed better in studies that were conducted in 
developed countries than in underdeveloped countries.  It is well known that the performance 
characteristics of any test vary markedly with the prevalence of the condition in the population 
being assessed (Khuroo et al., 2015).  In the end, performances varied widely among individual 
point-of-care tests for diagnosis of HCV infection, and physicians should consider this when 
using specific tests in clinical practice (Khuroo et al., 2015).  A secondary HCV-RNA 
confirmation test is necessary to determine acute versus chronic disease state prior to treatment 
evaluation.  
The Agency for Healthcare Research and Quality commissioned two systematic reviews 
on screening for and treatment of HCV infection in asymptomatic adults (Moyer, 2013).  This 
study analysis focused on evidence gaps identified in the previous USPSTF recommendations 
and new studies published since 2004 (Moyer, 2013).  
Moyer (2013) disclosed that the USPSTF found limited evidence on the harms of 
screening for HCV; however, potential harms could include anxiety, patient labeling, and 
feelings of stigmatization (Moyer, 2013).  The USPSTF found adequate evidence that antiviral 
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therapy regimens are associated with a high rate of harms, such as fatigue, headache, ﬂu-like 
symptoms, hematologic events, and rash; however, Moyer (2013) further affirmed that when 
antiviral therapy is given for a deﬁned duration, serious adverse events are uncommon, and 
adverse events are self-limited and typically resolve after treatment is discontinued.  Moyer 
(2013) stated adequate evidence is found that these harms of treatment are small.  
Moyer (2013) asserted that as treatment of HCV continues to evolve, “more research is 
needed to understand which persons beneﬁt the most from treatment and when treatment should 
begin in asymptomatic persons” (p. 352).  Other research gaps include a focus on long-term 
harms associated with antiviral regimens and an exploration of the frequency of testing in high-
risk populations (Moyer, 2013).  These specific topics are currently being explored.  
The indirect chain of evidence explored by USPSTF reveals significant beneﬁts of 
screening through improvement of the intermediate outcome of SVR after triple-regimen 
antiviral treatments and a reduction in liver-related mortality and hepatocellular carcinoma 
(Moyer, 2013).  The USPSTF determined that the new evidence supports a moderate magnitude 
of net beneﬁt for the 1945–1965 birth cohort as well as for high-risk persons (Moyer, 2013).  
Clinical practice guidelines. Although the meta-analysis from the USPSTF was 
discussed previously by Moyer (2013), it is essential to describe the actual clinical practice 
guidelines from the meta-analysis outcomes.  Clinical practice guidelines developed from 
USPSTF recommendations include screening for HCV infection in persons at high risk for 
infection as well as offering one-time screening for HCV infection to adults born between 1945 
and 1965 (USPSTF, 2016).  The USPSTF makes recommendations about the effectiveness of 
specific preventive care services for patients without related signs or symptoms and bases its 
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recommendations on the evidence of both the benefits and harms of the service and an 
assessment of the balance (USPSTF, 2016).  
The rationale for these recommendations is that HCV is the most common blood-borne 
pathogen in the United States and a leading cause of complications from chronic liver disease 
including death.  It further reports that according to data collected from 1999 to 2008, about three 
fourths of patients in the US living with HCV infection were born between 1945 and 1965 
(USPSTF, 2016).  One screening strategies is to target persons with risk factors for HCV 
infection, including past or present injection drug use (even if just one time), sex with an 
injection drug user, blood transfusion before 1992, and now, birth cohort 1945–1965.  Additional 
risk factors include long-term hemodialysis, being born to an HCV-infected mother, 
incarceration, intranasal drug use, getting an unregulated tattoo, and other percutaneous 
exposures (Moyer, 2013).  The financial burden of undiagnosed HCV far exceeds the cost of 
treating for a cure. 
Screening for HCV should be voluntary and with the patient’s understanding that HCV 
testing is planned.  Patients should be informed that HCV testing will be performed unless they 
decline (opt-out screening).  The USPSTF believes that before HCV screening, patients should 
receive an explanation of HCV infection, how it can (and cannot) be acquired, the meaning of 
positive and negative test results, and the benefits and harms of treatment (Moyer, 2013).  
Patients should also be offered the opportunity to ask questions and to decline testing (Moyer, 
2013).  The USPSTF decided to upgrade HCV screening to a Grade B as there is high certainty 
that the net benefit to screening is moderate or there is moderate certainty that the net benefit is 
moderate to substantial (USPSTF, 2016).  
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As part of a broader global public health response, the WHO (2014) published Guidelines 
for the Screening, Care and Treatment of Persons with Hepatitis C Infection to provide a 
framework that can allow for the expansion of clinical services to patients with HCV infection.  
These guidelines provide key recommendations on HCV and considerations for implementation 
of screening, care, and treatment.  The WHO (2014) aims to ensure a comprehensive and 
sustainable response to viral hepatitis with focus on low- and middle-income countries.  WHO 
guidelines align with those of other global public healthcare organizations seeking to impact the 
HCV epidemic.  
 In 2012, the CDC updated recommendations for HCV guidelines.  The amended testing 
recommendations include one-time HCV testing for all persons born 1945–1965 regardless of 
other risk factors (CDC, 2013).  The CDC issued this update in light of (a) changes in the 
availability of certain commercial HCV antibody tests, (b) evidence that many persons who are 
identified as reactive by an HCV antibody test might not subsequently be evaluated to determine 
if they have current HCV infection, and (c) significant advances in the development of antiviral 
agents with improved efficacy against HCV (CDC, 2016).  The CDC and WHO provide 
evidence-based findings to assist policy makers, governments’ and other public health systems 
for best practice outcomes.  
In 2013, the Journal of Nurse Practitioners published an update of HCV screening and 
guidelines.  Karen Hande DNP, ANP-BC, gave the latest CDC screening guidelines update for 
clinical practice.  The CDC guidelines recommend that initial HCV testing should be done with a 
Food and Drug Administration–approved test for an antibody to HCV (anti-HCV Ab) due to its 
highly sensitive and specific laboratory-based assay reported as reactive or nonreactive (Hande, 
2014).  Nonreactive anti-HCV Ab results require no further testing, as it indicates the patient is 
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negative for HCV infection.  However, patients with risk for ongoing or recent HCV exposure or 
persons who are severely immunocompromised may have false negative anti-HCV Ab test 
results and warrant an HCV-NAT due to high suspicion of HCV infection (Hande, 2014).  
Understanding the pathway of results is as follows: a reactive anti-HCV Ab is considered to 
either indicate the patient has a current HCV infection or has had an HCV infection in the past.  
Both warrant serum HCV-NAT testing.  Hande (2014) reported if serum HCV-NAT is negative, 
then this confirms patient has at some point had an HCV infection that has resolved.  HCV clears 
in 15%–25% of acutely infected persons.  Important to note is that anti-HCV Ab testing does not 
distinguish between persons with a past infection that self-resolved and persons currently 
infected with HCV (Hande, 2014).  Only HCV-NAT can make this determination.  In conclusion, 
early identification, linkage to care, education, and clinical evaluations are critical disease 
prevention interventions that nurse practitioners (NPs) can provide to patients (Hande, 2014).  
Cross-sectional study. A study conducted by Galbraith et al. (2015) describes the early 
experience with an integrated, opt-out HCV screening and linkage-to-care program of baby 
boomers in an urban ED.  This is the first study to broadly and systematically screen ED baby 
boomer patients for HCV and provide linkage to HCV care (Galbraith et al., 2015).  
Galbraith et al. (2015) confirms the large-scale, targeted testing of the baby boomer birth 
cohort has further revealed racial and health care coverage disparities among the newly HCV-
diagnosed populations in the ED.  ED HCV screening has many inherent challenges, including 
the costs of screening, the competing priorities of ED care, and the development of a linkage-to-
care infrastructure (Galbraith et al., 2015).  
Randomized control trials. The objective of the ASCEND trial (A Phase IV Pilot Study 
to Assess Community-Based Treatment Efficacy in Chronic Hepatitis C Mono-infection and 
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Coinfection with HIV in the District of Columbia) was to determining efficacy of HCV treatment 
independently provided by NPs, primary care physicians (PCPs), or specialist physicians using 
DAA therapy was conducted in 13 urban, federally qualified health centers in Washington, DC.  
This open-label clinical trial initiated in 2015 with a referred sample of 600 patients, of whom 
96% were black, 69% were male, 82% were treatment naive, and 20% had cirrhosis (Kattakuzhy 
et al., 2017).  Patients were assigned in a nonrandomized but specified manner to receive 
treatment from one of five NPs, five PCPs, or six specialists (Kattakuzhy et al., 2017).  All 
providers underwent an identical three-hour training session based on guidelines and patients 
received treatment with ledipasvir-sofosbuvir, which was provided on site, according to U.S. 
Food and Drug Administration labeling requirements (Kattakuzhy et al., 2017).  Measurements 
were based on SVR. 
The primary efficacy end point was SVR, defined as an undetectable HCV-RNA viral 
load 12 weeks after treatment completion, and patients with detectable HCV-RNA at the SVR 
time point were considered to have viral relapse (Kattakuzhy et al., 2017).  Secondary end 
points, according to Kattakuzhy et al. (2017), included evaluation of efficacy by subgroups: 
provider type, treatment duration, HIV serostatus, cirrhosis, and adverse events.  The trial was 
sponsored by the National Institutes of Health Clinical Center, approved by the Institutional 
Review Board (IRB) of the National Institute of Allergy and Infectious Diseases, and conducted 
in compliance with the provisions of the Declaration of Helsinki good clinical practice guidelines 
and local regulatory requirements (Kattakuzhy et al., 2017)  
Kattakuzhy et al. (2017) described the following results.  Six hundred patients were 
assigned to receive ledipasvir-sofosbuvir from an NP (n = 150, 25%), a PCP (n = 160, 27%), or a 
specialist (n = 290, 48%) and of the 600, 516 (86%) achieved SVR.  The other 84 patients did 
 A HEPATITIS C SCREENING TOOL FOR AN UNINSURED POPULATION 
  26 
not achieve the primary end point due to (a) lost to follow up (45, 54%), (b) viral relapse (n = 35, 
42%), or (c) death (n = 4, 4%).  Provider-prescribed SVR outcome ratios were NP = 89.3%, PCP 
= 86.9%, and specialists = 83.8%.  Little difference was noted between providers for HIV 
coinfected or cirrhosis patient outcomes.  Interestingly, patient treatment adherence was noted to 
be highest with NP providers (73.9%), followed by PCPs (63.1), and specialists had the lowest 
adherence to treatment (55.9).  The data collected have the potential for multiple variations for 
analysis.  
This study reports to be the first clinical trial to demonstrate a high rate of SVR among 
patients of PCPs and NPs providing independent HCV care using DAAs (Kattakuzhy et al., 
2017).  The high cure rate achieved by non-specialist providers was maintained even with 
HIV/cirrhosis coinfections.  The study was conducted within the setting and time limitations of 
standard medical practice, without the use of patient navigators, in federally qualified health 
centers serving an urban, socioeconomically challenged population, thus demonstrating the 
feasibility of delivering DAA treatment in these existing sites (Kattakuzhy et al., 2017). 
The ASCEND investigation suggests that provider restrictions for prescribing DAAs to 
treat HCV are not supported by evidence and stand as an unnecessary barrier in the treatment of 
HCV.  Seeking alternative treatment options is the only way to eliminate HCV.  
Quasi-experimental trials. A descriptive analysis of a community clinic providing HCV 
treatment to poor and uninsured patients by Sims, Melton, and Ji (2018) described a 
multidisciplinary approach at Mercy Health Center in Northeast Georgia to provide therapy for 
the uninsured.  Mercy Health Center is a nonprofit community clinic that provides primary and 
specialty care services, including an HCV team, free of charge to patients who are uninsured, at 
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or below 150% of federal poverty level, and reside within the six-county service area (Sims et 
al., 2018). 
Of the 69 HCV patients found HCV positive in the Sims et al. (2018) study, a large 
majority were baby boomers born between 1945 and 1965 (67%), and nearly half acquired HCV 
due to illicit drug use (Sims et al., 2018).  More than a third of patients received HCV treatment, 
of which 81% completed treatment with 85% of completers achieving SVR.  The treatment team 
successfully secured free HCV medications from pharmaceutical patient assistance programs for 
all patients who completed assessments.  Despite comorbidities and psychological disorders, the 
vast majority achieved SVR (Sims et al., 2018).   
With appropriate support, it appears poor and uninsured patients living with HCV, who 
are often regarded as difficult-to-treat, can achieve HCV treatment completion and SVR rates 
similar to those of insured HCV patients (Sims et al, 2018).  Unfortunately, patients living with 
HCV who are characterized as difficult-to-treat are often denied or deferred treatment due to 
their complex economic, psychosocial, medical, and psychosocial needs; thus, a 
multidisciplinary approach is ideal for optimal patient care (Sims et al, 2018).  
A common theme repeated in the Sims et al. (2018) study and many others is the lack of a 
federally funded comprehensive care system available for uninsured patients living with HCV 
comparable to the widely available programs for uninsured HIV patients.  Limitations reported 
by Sims et al. (2018) for this study include its retrospective study design, small sample size, and 
absence of available data on substance type for history of substance abuse.  Other limitations 
include a single site setting that limits the generalizability of findings to broader populations 
(Sims et al., 2018).  The conclusion of this study reiterates the urgency of finding methods to 
secure HCV screening and treatment therapy.  In the coming years, access to costly HCV 
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medications will likely determine how wide or narrow the gap will be between those who are 
cured of HCV and those who will continue to suffer from HCV-related liver disease (Sims et al., 
2018).  Advocacy for funding and policy change along with attempts to find alternative 
approaches to reach difficult-to-access HCV populations will help close the gap. 
Other evidence. Several articles regarding testing and guidelines have been published to 
educate on and create awareness of HCV.  Dan et al. (2015) developed a resource for continuing 
education titled “Viral Hepatitis: New U.S. Screening Recommendations, Assessment Tools, and 
Treatments” designed to inform and educate medical professionals.  The Institute of Medicine 
reported viral hepatitis as an underappreciated public health problem, highlighted multiple 
barriers to viral hepatitis prevention and control, and provided specific recommendations to 
improve efforts to stop the spread of viral hepatitis (Dan et al., 2015).  The National Viral 
Hepatitis Action Plan was devised by Health and Human Services and was last updated in 2014.  
The action plan sets goals within six major priority areas and provides a framework upon which 
stakeholders can their focus efforts (Dan et al., 2015).  Dan et al. (2015) reported that as 
providers “work to understand the true burden of HCV in the United States and how to better 
target the use of limited resources, accurate diagnosis and appropriate reporting are paramount” 
(p. 31).  Nurses play a pivotal role in all six priority areas; as educators, care coordinators, and 
health care providers, they are uniquely positioned to provide critical leadership in advancing our 
nation’s efforts to address the silent epidemic of viral hepatitis (Dan et al., 2015).  
Further discussion on HCV guidelines is provided by Hellard et al. (2017).  Support for 
use of health-related goals is the premise for pursuing HCV elimination by 2030.  In late 2015, 
world leaders at the United Nations adopted the 2030 Agenda for Sustainable Development.  
Specifically, Sustainable Development Goals 3.3 aims to ensure healthy lives and promote well-
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being at all ages and highlights the need to combat viral hepatitis (Hellard et al., 2017).  The 
WHO, in response, developed the first-ever Global Health Sector Strategy on Viral Hepatitis, 
2016–2021, which was endorsed by the World Health Assembly in May 2016 (Hellard et al., 
2017).  WHO’s vision is for a world where viral hepatitis transmission is halted, and everyone 
living with viral hepatitis has access to safe, affordable, and effective prevention, care, and 
treatment services (WHO, 2016).  The challenge in moving this agenda forward has been the 
quantity and quality of data to inform the testing recommendations, and the guidelines in Hellard 
et al.’s (2017) article highlight the evidence and research gaps to create an agenda for the future.  
The goal of elimination of HCV by 2030 is feasible, and the WHO testing guidelines inform 
elimination strategies at individual health services facilities and at national and regional levels 
(Hellard et al., 2017). 
Also noteworthy is an article specifically on appropriate screening simply titled 
“Hepatitis C Screening” by Shoba N. Joshi (2014).  Joshi (2014) stated, “Screening is 
characterized by interventions in a group of individuals with no signs and symptoms of disease 
to identify unrecognized disease” (p. 664).  Screening is not intended to be diagnostic; it is to 
detect the possibility of HCV exposure based on risk behaviors, exposure potentials, and birth 
cohort.  Although most clinicians have extensive experience with disease diagnosis and 
management of disease, Joshi (2014) stated that “they have limited experience with screening for 
disease” (p. 664).  The article creates awareness of the WHO, CDC, and USPSTF guidelines.  
The hope is that by appropriate identification of HCV before the onset of signs and symptoms, 
morbidity and mortality can be reduced (Joshi, 2014).   
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Synthesis 
The literature review establishes that the single most important factor in the battle against 
HCV is screening.  Without a solid screening approach, the elimination of HCV is just an idea.  
Currently, too many people are excluded from the recommended screening.  The literature 
reveals that the setting of HCV screening has a big impact on the uninsured population.  
Hepatologist, oncologist, and even PCP offices are the most common settings for HCV 
screening.  Nevertheless, the evidence in the literature supports alternative approaches to 
reaching the underserved population of the uninsured.  Research reports utilization of the ED and 
a new outreach approach, mobile medical clinics, are useful methods to reach the difficult-to-
access population.  Further literature exploration revealed key barriers to HCV screening 
includes lack of provider awareness and/or knowledge of the severity of HCV and 
recommendations for care.  
Settings for HCV screening. Literature supports the idea that alternative approaches to 
reach and screen populations at risk for HCV are necessary.  Primary care clinics are standard 
sites for screening, but if there are not enough PCPs in a given community, a large underserved 
population is created.  Simplifying approaches to offering immediate screening in alternative 
settings is essential to capture the uninsured and underserved at-risk group.  Morano et al. (2014) 
determined “while there was no difference in HCV prevalence among the type of HCV testing 
strategy selected, those selecting point-of-care testing were signiﬁcantly more likely (93.8 vs. 
18.2 %; p\0.0001) to be linked to HCV specialty care” (p. 928).  Point-of-care testing peovides 
immediate results, leading to more accountability for personal health.  Morano et al. (2014)’s 
article also disclosed findings that patients “accepting HCV testing were positively and 
signiﬁcantly correlated with having been diagnosed with a STI [sexually transmitted infection], 
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being US born, and being a PWID [person who injects drugs]” (Morano et al., 2014, p. 923).  
Settings difficult-to-access populations may frequent include EDs, free clinics, and mobile units. 
Emergency department settings. HCV screening initiatives in settings such as the ED 
can play a crucial role in identifying infected patients.  The ED acts as a health care safety net for 
many difficult-to-access patients who do not seek medical care services outside the ED (Cornett 
et al., 2018).  Cornett et al. (2018) was the first study conducted in a nonurban/epicenter ED on 
HCV screenings.  Previous studies were all conducted in “large urban hospitals that serve many 
patients known to be at higher risk for HCV infection, including injection drug users, minorities, 
and persons of low income” (Cornett et al., 2018, p. 2).  The aim of Cornett et al. (2018) study 
was to determine whether routine HCV screening of the baby boomer birth cohort is warranted 
in EDs located outside large urban cities (Cornett et al., 2018).  The results showed positive 
findings in support for HCV screening and indicate that EDs outside large urban hospitals are 
important sites to increase identification of patients with HCV (Cornett et al., 2018).  To date, 
there remain very few studies on rural ED screening measures.  Owing to the higher 
unemployment rate, poverty level, and rate of lack of insurance in these remote areas, it seems 
logical that rural ED may be a strong source to capture hard-to-reach individuals. 
Primary care settings. Primary care health centers continue to be target sites for HCV 
screenings, yet routine testing is not carried out.  In one study, five federally qualified health 
centers in Pennsylvania integrated a model developed from the CDC testing and linkage 
initiative and successfully identified a large number of HCV-positive patients, which confirmed 
that testing in health clinics is an important way to identify people previously undiagnosed 
(Coyle, Kwakwa, & Viner, 2016).  Prior to integrating HCV testing, the researchers took three 
steps: (1) training health center staff members about HCV etiology and epidemiology, as well as 
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project goals and model implementation plan; (2) negotiating with commercial laboratories that 
were paid with grant funding on pricing for HCV tests performed on uninsured patients; and (3) 
deciding if universal or risk-based HCV testing was the most efficient testing method (Coyle et 
al., 2016).  The buy-in of health staff supported the model’s success.  Participating centers all 
represented at-risk populations in a large urban county; therefore, portions of this model may not 
be able to be replicated in different settings or other areas of the country (Coyle et al., 2016).  To 
implement new models promoting recommended HCV screening requires specific design 
methods in alternative settings and for targeting setting populations.   
New alternative mobile setting. New opportunities to reach high-risk marginalized 
populations outside traditional health care settings have emerged with the development of a 
highly sensitive and specific rapid, point-of-care HCV antibody test (Morano et al., 2014).  
Medical mobile clinics are growing in attractiveness as an alternative resource in underserved 
rural communities.  MMCs are nontraditional healthcare units that increase healthcare access by 
removing geographic and social barriers associated with traditional brick-and-mortar settings 
(Morano et al., 2014).  By providing preventative healthcare and treatment services, MMCs play 
a critical role in delivering health care to the poor, the homeless, migrant workers, the 
underserved, and uninsured patients that are otherwise “limited by location, cost, insurance 
status, literacy, stigma or other structural barriers such as proximity and access to transportation” 
(Morano et al., 2014, p. 923).  A New Haven, Connecticut study reported, “MMCs are highly 
acceptable to medically disenfranchised patients and provide immediate point of care treatment 
for patients across a range of medical conditions, including HCV screenings” (Morano et al., 
2014, p. 928).  Reducing healthcare disparities and inequalities in rural communities can be 
 A HEPATITIS C SCREENING TOOL FOR AN UNINSURED POPULATION 
  33 
achieved with alternative delivery settings and can further assist with the WHO’s goal to 
eradicate HCV. 
Knowledge deficit. Evidence also suggests that vast knowledge deficit from health care 
professionals is a topic relevant to HCV screening.  A recent qualitative study of “personal 
experiences and challenges confronted by predominantly uninsured and racial-ethnic minority 
baby boomers newly diagnosed with chronic HCV reveals multiple opportunities to improve 
education and support” from healthcare professionals (Turner et al., 2017, p. 4609).  Health care 
professionals’ lack of knowledge of and comfort level in addressing HCV is a struggle.    
Changing guidelines and revolving best practice policies leave professionals uncertain of what 
information to utilize. Innovations in HCV treatment have made it the disease the first chronic 
viral infection to be reliably curable through pharmacotherapy with newer DAA medications, 
which demonstrate cure rates approaching 100% (Naghdi et al., 2017).  Nevertheless, without 
education and knowledge of available screening tests and treatment options, HCV will continue 
to burden society.  The results of the study by Naghdi et al. (2017) highlight several areas where 
health care professionals perceive a high need for training in areas including screening, patient 
education, and treatment.  Naghdi et al. (2017) reported “different levels of confidence” in the 
various  screening recommendations and found that “overall, there was a need for further 
education, particularly for primary care physicians, to maximize the role that they can play in 
screening, testing, and treatment of hepatitis C” (p. 1).  Even with rapid advances in HCV 
science, including new treatment modalities, ensuring that the treatments are reaching 
individuals who would most benefit from them presents a challenging educational problem 
(Naghdi et al., 2017).   
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Screening tool innovation. The USPSTF increased screening recommendations to 
include the birth cohort 1945–1965/baby boomers in the category of at-risk persons, but lack of 
funding remains a key barrier.  “Having health insurance or not was the only factor that 
determined whether an individual pursued downstream care or not following a positive [HCV] 
result” (Ditah et al., 2015, p. 1131).  These findings reveal further evidence that the uninsured 
population requires resources beyond what is currently available.  Development of screening 
tools tailored for alternative settings will help capturing patients that may go unscreened.  The 
CDC (n.d.) has made available on their website a hepatitis risk assessment tool for health care 
providers to use for guidance.  This particular tool emcompasses hepatitis A, B, and C virus 
concerns.  There were no risk assessment tools specifically for HCV discovered, only repeated 
recommedations.   
Conceptual Model 
Less fortunate patients in rural Petersboro County do not receive the CDC- and USPSTF-
recommended HCV screening.  Lack of accessibility, equity, and/or knowledge of the disease 
process leads to disparity in health care.  The purpose of this project is to determine if using a 
screening tool will create a tangible reminder to increase evaluation efforts at the SFMC.  The 
objective was to utilize the HCV screening tool to increase the number of patients screened 
during the April 13, 2019, clinic period.  
The Iowa Model of Evidence-Based Practice was applied as the conceptual framework to 
address this problem and achieve the objective.  The Iowa Model embodies the necessary content 
to execute putting research into practice.  With health care practices evolving, major professional 
and health care organizations as well as federal agencies and policy-making governing bodies are 
emphasizing the importance of evidence-based practice (Fineout-Overholt, Melnyk, & Schultz, 
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2005).  Developing a program to support best outcomes for patients requires a collaborative 
approach with organizational and individual buy-in from leadership and staff.  The Iowa Model, 
collaborative in nature, contains both problem- and knowledge-focused triggers that steer 
questioning of current practice and ask whether patient care could be improved using evidence-
based research (Clanton, 2014).  There is a constant challenge in the practice setting to provide 
measurable care and outcomes of the highest standard in an evidence-based manner (Doody & 
Doody, 2011).  The seven steps of the Iowa model promote challenging current norms to 
improve quality of care.  For evidence-based practice to be implemented, the value of “providing 
high quality care based on best practice must be a priority and this is the responsibility of each 
practitioner in any given situation” (Doody & Doody, 2011, p. 665).  Permission to use the Iowa 
Model conceptual framework was granted on May 24, 2018, by the University of Iowa 
Department of Nursing (see Appendix A).  
The team formed was an interdisciplinary group of medical staff at SFMC led by a 
Doctor of Nursing practice student.  The task force team consisted of two medical doctors, one 
Chiropractor, one Doctor of Nursing Practice student, four registered nurses, and one lab 
technician.  Each team member showed efficacy in HCV knowledge, utilization of the screening 
tool, and the intervention design through pre- and post-testing.  
 The HCV Screening Tool was developed based on recommendations and guidelines 
retrieved from the CDC, USPSTF, and WHO.  Pre- and posttest surveys were created by the lead 
investigator (see Appendix G). 
Staff were verbally recruited prior to implementing the pretest.  Next, a training session 
was conducted, and then a posttest survey was administered to the task force group to ensure 
they had an appropriate knowledge base.  Review of completed posttest forms were in real time 
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and reeducation was not needed.  The HCV Screening Tool was utilized in the clinic to screen 
patients for HCV testing. 
Utilizing statistical software for data analysis included entry of data collected on HVC 
screening form and pre/post test data.  Findings are disseminated in the form of a scholarly 
dissertation. 
Summary 
 Implementing HCV screening recommendations from the CDC and the USPSTF is 
essential to eliminate suffering from end-stage liver disease from untreated chronic HCV.  
Recent literature reveals the need to seek alternative settings for HCV screening of asymptomatic 
patients born within the birth cohort 1945–1965 and those with at-risk lifestyle behaviors.  
Development of a screening tool designed for specific settings was necessary to ensure target 
population testing efficacy.  The literature review supports the need for this project to utilize a 
paper HCV screening tool to evaluate HCV at-risk patients at SFMC.  
SECTION THREE: METHODOLOGY 
Design  
Utilizing the Iowa Model for Evidence-Based Practice, an HCV screening intervention 
was implemented at SFMC.  The Iowa Model guides clinical decision-making and evidence-
based processes from both the clinician and system perspectives (Iowa Model Collaborative, 
2017).  The research design was nonexperimental.  Categorical data was gathered through a tool 
developed by the lead investigator based on the current CDC and USPSTF guidelines to screen 
persons for at-risk behaviors.  
Prior to the screening tool intervention, a volunteer board member at SFMC who is a 
registered nurse performed a retrospective chart audit for a previous month to determine the 
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number of patients screened for HCV and the total number of patients seen in the clinic.  The 
morning of screening implementation, the lead investigator presented a pretest of 12 questions 
regarding HCV to the clinical staff before clinic opened.  Pretests were collected, and then an 
educational session was conducted using handouts from the CDC on HCV.  Information included 
what HCV is and is not, the need for screening, and use of the screening tool were discussed.  A 
12-question posttest was utilized to determine the clinical staff’s comprehension of the HCV 
training session to ensure all screeners were using the same criteria. 
The Samaritan Free Medical Clinic Hepatitis C Screening Tool (SFMC-HCV-ST) was 
printed on light purple paper and attached to the front of each patient chart upon check-in.  Task 
force members volunteered to assist with this project through verbal recruitment.  No funding 
was needed for the screening tool project.  Outcome data collected on the SFMC-HCV-ST were 
collected by an assigned task force member to ensure no personal identifying information was 
transcribed.  Patients had the opportunity to opt out of screening. 
Measurable Outcomes  
1. After completion of the April 13, 2019, HCV screening tool intervention, a greater 
percentage patients’ in the SFMC will be screened for HCV.  This will be evidenced by the 
number of patients screened with use of the screening tool as compared to the number of patients 
screened previously without use of a screening tool. 
2. After completion of the educational program on HCV, clinic staff will show an increase 
in knowledge about HCV, the screening process, and the use of the screening tool.  This will be 
evidenced by a score of 91.5% or better on all posttests.   
A retrospective chart audit was performed to establish the number of persons registered 
for evaluation, their birth year, documented history of HCV, and whether HCV screening was 
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conducted at the clinic during February 2019.  The aim was to gather information for comparison 
of the variable in a two-group sample.  Data from the audit were collected on an Excel 
spreadsheet template and stripped of all identifiable data by a clinic board member. 
Setting  
SFMC offers completely free medical services to all patients, regardless of income, in 
Petersboro County, North Carolina.  SFMC came about as a result of an effort and desire by a 
local doctor to help those who are less fortunate and hurting in the community.  The entire clinic 
is run by volunteer services.  Donations from many churches, civic groups, and community 
organizations have helped keep the clinic open as a nonprofit 501(c)(3).  The goal is to help 
maintain good health, and the mission statement addresses the need to address community health 
through individuals.  Implementing the HCV screening tool aligns with the organization’s efforts 
to offer care that would not otherwise be possible.  A copy of the project site letter of support is 
provided in Appendix B.   
Population  
The uninsured and underserved patients of Petersboro County utilizing the SFMC was the 
population of interest.  Lack of resources for preventive services is a common burden, and with 
the SFMC-HCV-ST and partnership with Advancing Lives. Fighting Aids (ALFA), the 
population will be a step closer to healthcare equality.  A convenience sample including all 
registered patients on the select day of screening was used for ease of accessibility.  All patients 
meeting the HCV screening criteria were referred to ALFA Red Van for HCV point-of-care 
testing.  ALFA uses their own informed consent for testing.   
Clinical task force members enlisted included two medical doctors, one chiropractor, one 
doctor of nursing practice student, five registered nurses, and one lab technician.  The Doctor of 
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Nursing practice student led this intervention project.  To assure task force members understood 
the intervention dynamics, an education session covering the HCV disease process, 
recommendations for HCV screening, use of the HCV screening tool, and implementation 
process was conducted on the morning prior to clinic opening.   
Ethical Considerations 
The Doctor of Nursing Practice project team (student and project chair) completed 
research ethics training to ensure protection of human subjects, Collaborative Institutional 
Training Initiative certificate is provided in Appendix C.  Further, the project was submitted to 
and received approval from the Liberty University IRB.  A copy of the IRB approval letter is 
provided in Appendix D. 
Ethical considerations for the protection of human subjects, consent, and data 
confidentiality were reviewed across multiple stages of data collection to ensure no identifying 
personal information was obtained.  Informed consent was obtained for HCV screening, and a 
separate consent was required by the ALFA organization to perform point-of-care testing.  The 
SFMC has patients sign consent for treatment as part of the registration process.   
Retrospective and real-time data are protected by a numeric system starting with the 
month and day of visit followed by 01, 02, 03, 04, etc.  The coded number (e.g., 0413-01, 0413-
02, 0413-03, etc.) was placed at the top of each screening tool by lead investigator.  Further, a 
HIPAA-compliant computer was used for data entry into the IBM-SPSS software and was also 
password protected.  Information forms were shredded once data entry into SPSS was 
completed.  Data entry information will be kept for three years as required and then deleted.  No 
patient or staff information will be reported in any future presentations or publications.  
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Data Collection  
Patients registered for medical treatment were given a recruitment letter to read while 
waiting.  The HCV screening tool and consent form were placed on each chart by intake nurse, 
who then completed the screening tool after consent was obtained.  Data were gathered in real 
time on the HCV screening form.  Final collected data forms were reviewed to ensure no 
personal identifying information was present.  Each patient was given the opportunity to opt out 
of screening.  
Tools 
HCV screening tool. The review of the literature for current screening tools resulted in 
limited findings: Only the CDC and the USPSTF guidelines were located.  These guidelines 
were utilized for creation of SFMC-HCV-ST, which was developed using Epi Info 7 public 
software.  The template is provided in Appendix E.  An algorithm approach was chosen for 
simplicity as the foundation of the form’s development.   
Pretest and posttest. A pretest and posttest were developed to assess provider 
knowledge gained during the education session.  This style of evaluation was chosen for ease of 
use, high efficacy, and reliability with qualitative analysis.  Both tests were developed by the 
Doctor of Nursing Practice student using Epi Info 7 public software and can be found in the 
Appendix F. 
Retrospective audit tool. A preintervention audit was conducted retrospectively for the 
February 2019 clinic month to determine how many patients were screened for HCV.  Only 
pertinent information was collected, including birth year, recorded history of HCV or intravenous 
drug use, and whether HCV screening took place during that visit.  Data were collected on an 
Excel spreadsheet.  
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Intervention  
The collaboration between the ALFA mobile medical unit and SFMC is a practical 
agreement to improve the quality of care for the underserved community.  The clinic patients are 
not receiving recommended preventative HCV screenings due to funding constraints that the 
grant-funded ALFA mobile medical clinic could provide.  Working together to offer necessary 
health care services to the less fortunate aligns with both organizations’ missions and represents a 
step toward HCV screening equality.  Utilizing the CDC and USPSTF guidelines, a screening 
tool was developed using Epi Info 7 software by the lead investigator.  After securing IRB 
approval, training began with the clinical task force members the morning before clinic opened.  
To assure clinical task force members understood the intervention dynamics, an open education 
session covering the HCV disease process, recommendations for HCV screening, and the use of 
the HCV screening tool was conducted.  Assignment of task force members took place on the 
morning of implementation.  Every effort was made to secure the same task force members for 
the entirety of the data collection period.  Consistency aids in reliability and the validity of data 
collection. 
Timeline of project stages. In alignment with the Iowa Model, the doctor of nursing 
practice student, who was the team leader, identified the problem-focused trigger, determined it 
was a priority topic for the organization, created a team, formulated research, reviewed the 
available literature, and decided there was enough of a research base to continue with the 
project.   
Preparation. In preparation for the investigation, the following steps were executed 
based on the previously determined timeline: 
• January 30, 2019: Completed primary defense with chair 
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• February 4, 2019: Submitted proposal to University’s IRB 
• February 13, 2019: Revisions sent per IRB request 
• February 24, 2019: Revisions sent per IRB request 
• March 13, 2019: Revisions sent per IRB request  
• April 10, 2019: Submitted proposal and university’s IRB acceptance letter to site (no site 
IRB), 
Implementation. In alignment with the Iowa Model, the evidence-based practice project  
was implemented.  The following steps were executed based on the previously developed 
timeline: 
• April 10, 2019: Collected chart audit (retrospectively for January 12, 2019) from 
designated individual at SFMC.  
• April 13, 2019: Conducted educational session with clinical staff at the SFMC and 
surveyed before and after the session. 
• April 13, 2019: Began utilizing the HCV screening tool.  
Evaluation. In alignment with the Iowa Model, the evidenced-based practice project was 
evaluated.  The following steps are in the process of being executed based on the proposed 
timeline: 
• By April 13, 2019: Analyzed postintervention data. 
• April 18, 2019: Finished the written scholarly project, completed editing and sent to the 
editor. 
• April 24, 2019: Editor returned paper with recommendations. 
• April 29, 2019: Final defense conducted. 
• April 29, 2019: Final revisions completed, and project posted to the Scholars Crossing 
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•  May 30, 2019: Disseminate to key stakeholders 
Feasibility analysis. The resources needed to carry out this intervention included but 
were not limited to the SFMC-HCV-ST, the pretest and posttest, and enough copies of the 
SFMC-HCV-ST for each registered patient on paper that was donated to the clinic.  Task force 
members were all volunteers and required no compensation.  Computer analysis of data was 
carried out by the lead investigator using her personal laptop and previously purchased statistical 
software.  The feasibility analysis for this project required no real money exchange. 
Data Analysis 
Analysis began with the immersion of collected data.  After careful review, data were 
coded for entry into a statistical software program.  Each collected form had the date of visit and 
number code; for data input the date was dropped and the remaining number became the 
numerical identification.  Retrospective data were entered into the statistical software program 
from the Excel spreadsheets, which included the following labels: form identification code, 
gender, birth year, reported history of HCV, and screened this visit.  After immersion in the 
prospective collected data, dependent variables included form identification code, gender, race, 
birth year, reported history of HCV, screened this visit, one risk behaviors, and two or more risk 
behaviors.  For the statistical computations, gender, race, reported history of HCV, and screened 
this visit labels were coded to numerical data responses under the value tab.  Risk behaviors were 
also coded numerically.  Analysis of descriptive statistics included frequency of patients screened 
and the creation of graphs to compare the differences between the data sets. 
Measurable Outcomes 
1. After completion of the April 13, 2019, HCV screening tool intervention, a greater 
percentage patients in the SFMC will be screened for HCV.  This will be evidenced by 
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the number of patients screened with use of the screening tool as compared to the number 
of patients screened previously without use of a screening tool. 
2. After completion of the educational program on HCV, clinic staff will show an increase 
in knowledge about HCV, the screening process, and the use of the screening tool.  This will be 
evidenced by a score of 91.5% or better on all posttests.   
SECTION FOUR: RESULTS 
Presentation of the data analysis will include the categorical survey results through 
various descriptive statistics with frequency.  This section will first discuss the results for the 
main premise of the study.  The aim of this project was to compare of two groups of data for 
significant differences that resulted from the independent variable, the screening tool.  
Demographics and the percentage of HCV guideline questions will be disclosed, and lastly, 
results of the clinic staff pretest and posttest will be analyzed for knowledge growth. 
 Retrospective data collected by chart audit for the clinic day of February 9, 2019 were 
entered into a statistical software program from an Excel spreadsheet.  The data entry process 
was repeated for the prospective data collected in real time on April 13, 2019 and included 
coding the screening questions based on HCV guidelines.  After data entry was complete, the two 
groups were analyzed multiple times for validity, and a statistician reviewed computations from 
the software program with manual calculations on a statistical calculator.  Findings were 
identical, which ensured reliability of the software and eliminated the possibility of investigator 
mathematical error. 
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Table 2 
Retrospective Group: No Screening Tool 02/19 
Valid? Frequency Percent Valid % 
Yes 13 25 25 
No 39 75 75 
Total 52 100 100 
  
Table 3 
Prospective Group: With Screening Tool 04/19 
 Frequency Percent Valid % 
Yes 43 82.7 87.8 
 No 6 11.5 12.2 
Total  49 94.2 100.0 
Missing 3 5.8  
Total 52 100  
 
The tables above display the collected data for each group.  The retrospective group had 
a total of 52 patient visits, of which 13 included screening for HCV; 39 did not include 
screening.  The prospective group had a total of 49 patient visits, 43 of which included screening, 
and six of which did not.  The significant change variable was the use of a screening tool for the 
prospective group.  Importantly, there were no missing data, only fewer patients visits on the day 
of prospective data collection.  The valid percent in the prospective group shows the correct 
percentage of 87.8%, which is the total percentage of patient visits that included the use of the 
screening tool.  The missing value of 3 was added to create an equal number of subjects between 
groups, as removal of 3 would create bias. 
Further analysis with descriptive statistics was limited.  Categorical dichotomous 
variables have only two unordered responses, making many statistical tests invalid for qualitative 
data.  Frequency tables give a better understanding of how often data occur and calculates 
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statistics including the mean, standard deviation, variance, and skewness of each data set.  
Skewness is a measure of how evenly distributed the data are or the shape of the bell curve for a 
normal distribution.  Table 4 expresses the skewness of each group. Table 4 
Group Data Frequency Statistics 
 Prospective Retrospective 
N   
Valid 49 52 
Missing 3 0 
Mean 1.12 1.75 
SEM .047 .061 
Median 1.00 2.00 
SD .331 .437 
Variance .110 .191 
Skewness 2.377 -1.189 
Std. Error of Skewness .340 .330 
Range 1 1 
 
Other tests included demographics and HCV guideline–specific questions with frequency 
percentage shown in Tables 5–7.  
Table 5 
Gender Ratio: Retrospective vs. Prospective Group 
 Retrospective Group  Prospective Group 
 Male Female Total  Male Female Missing Total 
Frequency 22 30 52  23 26 3 52 
Percent 42.3 57.7 100.0  44.2 50.0 5.8 100.0 
Valid percent 42.3 57.7 100.0  46.9 53.1   
Cumulative percent 42.3 100.0   46.9 100.0   
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Table 6 
Prospective Group: Risk Behaviors for HCV 
 Frequency Percent Valid Percent Cumulative Percent 
1945–1965 13 26.5 30.2 30.2 
Blood/Organ prior to 1990 2 4.1 4.7 34.9 
IV drug use or stuck with needle 5 10.2 11.6 46.5 
Multiple or same sex partners 1 2.0 2.3 48.8 
Live with HCV positive person 1 2.0 2.3 51.2 
None 21 42.9 48.8 100.0 
Total 43 87.8 100.0  
Missing  6 12.2   
Total 49 100.0   
  
Only the prospective group has data on guideline specific questions (Table 6) as well as clinic 
staff pretest/posttest analysis. 
 The morning of clinic April 13, 2019, clinical staff were verbally recruited to participate 
in pretest/posttest portion of the HCV screening tool intervention.  After immersion of the data, 
overall analysis started with comparing the pretest and posttest outcomes shown below in Table 
7. 
Table 7 
Pretest/Posttest Descriptive Statistics 
 N Range Minimum Maximum Mean SD Variance 
Pretest Scores 8 6 6 12 9.00 2.000 4.000 
Posttest Scores 8 1 11 12 11.63 0.518 0.268 
        
 
Pretest and posttest data were gathered in real time.  Clinic staff underwent an HCV 
education session after the pretest to establish baseline knowledge for HCV, and a posttest was 
given to assess education session knowledge gain.  Eight clinical staff providers participated as 
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the sample.  The mean score of the pretest was 75%, and the mean score of the posttest was 
95.8%.  
SECTION FIVE: DISCUSSION  
This project sought to determine if a screening tool would increase the rate of HCV 
screening in a rural free medical clinic.  A retrospective chart audit for February 9, 2019, and a 
prospective clinic intervention on April 13, 2019, were the sources of data for comparison.   
After careful analysis, the findings suggest the use of a screening tool increased the 
screening rate by 62.8% at SFMC.  Use of a visual aid to prompt providers for screening was the 
necessary addition to elicit this increase.  The difficult-to-access populations generally have no 
insurance and seek alternative settings for healthcare or misuse the EDs for health care needs.  
This places greater strain on the health care sector.  Clinical providers are overloaded with 
guidelines, and each new patient brings another best-practice pathway to pull from memory.  
Providing small interventions will revive the forgotten guiding principles recommended in an 
ever-changing health care structure.  Utilizing a pretest/posttest survey with a very brief 
educational session resulted in a knowledge increase of 20.8% in screening providers.  Small 
interventions like this project support best outcomes and offer an equitable approach to serve 
those with health care disparities.  
A conceptual model was utilized as a guide for this project.  The clinical decision-making 
and evidence-based practice processes of the Iowa Model aided both the clinical providers and 
organization through a multidisciplinary approach.  This model steers questioning of current 
practice in order to determine whether patient care could be improved using evidence-based 
research (Clanton, 2014).  Development of a screening tool based on CDC and USPSTF 
guidelines coupled with an educational intervention to ensure current clinical provider 
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knowledge aligns with the model chosen to guide this project.  Seeking alternative platforms to 
capture difficult-to-access populations is the only way the United States will have the 
opportunity to make an impact on HCV.  Small interventions like this project assist the global 
efforts to end the HCV epidemic. 
Implication for Practice 
Underfunded settings can use these findings as an example upon which to build 
alternative partnerships with other community services for treating difficult-to-access 
populations in collaboration.  Developing specific screening tools will offer reminders to clinical 
providers in practice.  Governing agencies must recognize uninsured and underserved 
populations in rural America are not getting nationally recommended screenings and preventive 
health care services.  Policy change for rural equity is long overdue, and public health nurses 
need to advocate for reform.  Educational opportunities are multiple.  From academic settings to 
small rural clinics, clinical reminders and educational opportunities play an important role in 
screening cues.  Implementing a revolving educational mindset will assist practice clinicians to 
accept the constantly changing health care structure.  Lastly, evidence-based practice in research 
can use small projects like this to build and grow opportunities to improve the future of health 
care.  The implications for practice are innumerable. 
Limitations 
 Limitations of this evidence-based study include that it assessed only one rural setting 
and, therefore, may not be representative of other settings or population. The sample size and 
number of data collection days are also viewed as limitations.  Having more collected data over a 
longer period would assist other areas of research with similar topics and narrow the results 
further.  Patients in the data groups could be represented more than once if they presented during 
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both clinic days.  Funding is a large limitation in duplicating this project for HCV screening, as it 
is unethical to offer screening without the ability to provide testing and linkage-to-care.  Testing 
for HCV in uninsured patients leaves the patient or facility to absorb the cost. 
Conclusion 
In the United States, millions of Americans have been infected by HCV, and less than 
half have been diagnosed (Turner et al., 2017).  The most unfortunate truth about the above 
statement is that HCV is curable.  The United States of America is a powerhouse with abundant 
resources in the world, and yet millions of people die a horrific death unnecessarily.  The 
suffering caused by end-stage liver disease is brutal.  The disease trajectory includes fluid-
overload ascites filling the abdomen, pushing the diaphragm into the chest cavity causing 
shortness of breath; nausea and vomiting; and severe itching of the skin with jaundice as organs 
fail until the body shuts down.  End-stage HCV is not a quick process can drag out over several 
years. The constant emotional, social, and family stress of waiting for the next debilitating 
episode to occur without warning, causing yet another hospitalization, can be prevented.  
Watching several patients experience this terrible death caused a great passion to advocate and 
drive change in the lead investigator.  The reality of HCV is anyone can get infected, and without 
screening for risk behaviors and early detection, millions will continue to suffer needlessly.  
Rural areas are heavily burdened with uninsured populations living in poverty.  Advanced 
nursing providers have a duty to care for all in need, including the less fortunate, ill-educated, 
and suffering.  Creating alternative approaches to achieve equity for the uninsured and 
underserved should be a priority when suffering can be avoided.  
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Dissemination Plan 
Dissemination presentation will take place at the next regularly scheduled board meeting 
to all stakeholders at SFMC on May 30, 2019, at 6:30 p.m.  SFMC staff and ALFA mobile 
medical team will receive dissemination findings on next clinic day after disclosure to board 
members. This paper will be published in Liberty University’s Scholars Crossing no later than 
May 8, 2019.  Other presentations may include poster submission, and podium presentations at 
up coming healthcare opportunities.  
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Appendix A: Permission to Use Iowa Model 
You have permission, as requested today, to review and/or reproduce The Iowa Model Revised: 
Evidence-Based Practice to Promote Excellence in Health Care. Click the link below to open. 
  
The Iowa Model Revised: Evidence-Based Practice to Promote Excellence in Health Care 
  
Copyright is retained by University of Iowa Hospitals and Clinics. Permission is not granted 
for placing on the internet. 
 
Citation: Iowa Model Collaborative. (2017). Iowa model of evidence-based practice: 
Revisions and validation. Worldviews on Evidence-Based Nursing, 14(3), 175–182. 
doi:10.1111/wvn.12223 
In written material, please add the following statement: 
Used/reprinted with permission from the University of Iowa Hospitals and Clinics, 
copyright 2015. For permission to use or reproduce, please contact the University of 
Iowa Hospitals and Clinics at 319–384–9098. 
Please contact UIHCNursingResearchandEBP@uiowa.edu or 319–384–9098 with questions. 
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Appendix E: SFMC-HCV Screening Tool 
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Appendix F: Pre- and Posttest 
 
 
Test Number                                                                                                                                               Title MD, DO, NP, RN, 
 
Hepatitis C Pre-Test
1.   Hepatitis C is a global 
epidemic affecting more than 
3.2 million people in the US 
alone.       
                        O True O False 
 
4. Hepatitis C is called a silent 
epidemic because people can 
get infected and not know it?             
                         O True O False 
7. Alt people born 
between 1945-1965 
should have at least a 
one-time screening test 
for hepatitis C (unless 
previously documented) 
                    O True C) False 
10. Intravenous drug use is the 
most common risk-factor for 
contracting hepatitis C? 
                        O True O False 
 
 
 
 
 
 
2. Hepatitis C can only be 
transmitted from drinking/ 
eating after someone that 
is Hepatitis C positive? 
                        O True O False 
5. People that received blood 
products after 1999 are at risk 
for exposure to hepatitis C and 
should be tested? 
                      O True O False 
8. Lack of symptoms are 
actually a barrier to screening 
for hepatitis C?  
                     O True O False 
 
11. Risk-behaviors for 
exposure to hepatitis C include 
all of the following: IV drug 
use, men having sex with men 
multiple sexual partners, 
blood products received 
before 1992.  and birth cohort 
1945-1965? 
                        O True O False 
 
 
 
3. Hepatitis C is a curable 
disease with early screening 
and treatment? 
                          O True O False 
6. Some people that get 
infected with hepatitis C are 
able to clear. or naturally rid 
the virus. but most people 
who get infected develop a 
chronic lifelong, infection. 
                       O True C) False 
9. A non-reactive. or negative. 
result on a hepatitis C point-of-
care test requires a second test 
to confirm negative results? 
                           O True O False 
12. Do you think you have a 
strong knowledge base when 
it comes to screening for 
hepatitis C? 
O yes 
O No 
O could use more education 
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Test Title 
 
Hepatitis C Post-Test 
 
1. Intravenous drug use 
is the most common risk-
factor for contracting 
hepatitis C? 
O True O False 
4. All people born 
between 1945-1965 
should have at least a 
one-time screening test 
for hepatitis C (unless 
previously documented) 
O True O False 
7. Hepatitis C is called a 
silent epidemic because 
people can get infected 
and not know it? 
O True O False 
10. Hepatitis C is a global 
epidemic affecting more 
than 3.2 million people in 
the U.S. atone. 
O True O False 
 
 
2. A non-reactive. or 
negative result on a 
hepatitis C point-of-care 
test requires a second test 
to confirm negative 
results?                                         
O True O False 
5. Some people that get 
infected with hepatitis C are 
able to clear. or naturally rid 
the virus, but most people 
who get infected develop a 
chronic lifelong. infection.   
O True O False 
8. Hepatitis C is a curable 
disease with early 
screening and treatment?                           
O True O False 
 
11. Risk-behaviors for 
exposure to hepatitis C 
include all of the following: 
IV drug use. men having sex 
with men, multiple sexual 
partners, blood products 
received before 1992. long-
term hemodialysis. and 
birth cohort 1945-1965?                                                  
O True O False 
3. Lack of symptoms are 
actually a barrier to 
screening for hepatitis C? 
O True O False 
 
6. People that received 
blood products after 
1999 are at risk for 
exposure to hepatitis C 
and should be tested? 
O True O False 
9. Hepatitis C can only be 
transmitted from 
drinking/ eating after 
someone that is Hepatitis 
C positive? 
O True O False 
 
12. Do you think you 
have a strong 
knowledge base when it 
comes to screening for 
hepatitis C? 
O yes 
O No 
O need more education
Questionnaire created from the CDC Hepatitis C Guidelines using EpiForm7.  
